Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 140.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 20.00 (14.286%)
Open: 150.00
High: 150.00
Low: 150.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON AIM WINNERS & LOSERS: CPPGroup Earnings To Beat Forecasts

Mon, 18th Jan 2021 10:41

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday.

----------

AIM WINNERS

----------

CPPGroup, up 46% at 478.00 pence. The insurance and financial services company said earnings for 2020 are expected to surpass market consensus, with the firm expecting 2020 earnings before interest, tax, depreciation, and amortization of between GBP7.1 million to GBP7.3 million, ahead of market forecasts of GBP6.4 million.

----------

Faron Pharmaceuticals, up 22% at 337.56 pence. The biopharmaceutical said the US Department of Defense has chosen the HIBISCUS Study to receive USD6.1 million of funding from the Coronavirus Aid, Relief & Economic Security Act. The phase II/III HIBISCUS trial will assess Traumakine, Faron's IV IFN beta-1a, for the treatment of hospitalised Covid-19 patients in the US.

----------

Mosman Oil & Gas, up 22% at 0.214 pence. The Australia and US-focused oil and gas explorer confirmed the completion of the sale of the Welch Project, in Texas, for USD420,000.

----------

Augean, up 10% at 206.25 pence. The waste management company said it expects to report an adjusted pretax profit for 2020 at least in line with the year before, despite the decline of its North Sea business and the ongoing Covid-19 pandemic. In 2019, Augean's adjusted pretax profit was GBP19.2 million.

----------

AIM LOSERS

----------

Velocys, down 26% at 7.64 pence. The sustainable fuels technology company said Shell International Petroleum has withdrawn from the Altalto Joint Development agreement. Velocys and British Airways will continue to work to secure finance for the Altalto Immingham plant, and will continue talks with potential finance sources.

----------

SEC Newgate, down 12% at 42.50 pence. The public relations firm said its two largest UK agencies, SEC Newgate UK - Newgate Communications - and Newington Communications, will merge and rebrand as SEC Newgate UK. As part of this, SEC Newgate will increase its stake in Newington to 100% from 60%, paying GBP420,799 for the 40% minority stake it did not already own.

----------

Remote Monitored Systems, down 8.7% at 2.74 pence. The data collection and surveying firm said the last test for its 4-ply mask, the biocompatibility test, has been delayed and is now expected to be completed in the next week. The mask manufacturing machine arrived from Lemu, as expected, and has been installed in Nottingham's BioCity, with work beginning this week to commission the machine and commence production.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
20 May 2020 10:37

Faron Pharmaceuticals confirms publication of 'crucial' study

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Wednesday that the results of its detailed analyses into the effects of glucocorticoids on intravenous interferon beta-1a activity, which arose following the 'INTEREST' trial in 2018, had been published in critical care journal Intensive Care Medicine.

Read more
11 May 2020 16:48

Faron Pharma Gets EUR800,000 Grant From Finnish Cancer Consortium

Faron Pharma Gets EUR800,000 Grant From Finnish Cancer Consortium

Read more
11 May 2020 16:03

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
5 May 2020 12:05

Faron Pharmaceuticals Picks Manufacturing Partner For Clevegen Therapy

Faron Pharmaceuticals Picks Manufacturing Partner For Clevegen Therapy

Read more
5 May 2020 09:20

Faron Pharmaceuticals inks manufacturing deal with AGC Biologics

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has selected contract development and manufacturing organisation AGC Biologics as the commercial-scale manufacturer of 'Clevegen', it announced on Tuesday.

Read more
27 Apr 2020 13:52

UK EXECUTIVE CHANGE SUMMARY: Corero Hires Former CML Finance Director

UK EXECUTIVE CHANGE SUMMARY: Corero Hires Former CML Finance Director

Read more
27 Apr 2020 13:51

UK TRADING UPDATE SUMMARY: Novacyt Called Upon To Ramp Up UK Testing

UK TRADING UPDATE SUMMARY: Novacyt Called Upon To Ramp Up UK Testing

Read more
22 Apr 2020 18:42

Faron Raises EUR14 Million In Oversubscribed Share Placing

Faron Raises EUR14 Million In Oversubscribed Share Placing

Read more
21 Apr 2020 18:21

Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million

Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million

Read more
1 Apr 2020 17:56

UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work

UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work

Read more
20 Mar 2020 11:25

Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss

Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss

Read more
20 Mar 2020 10:49

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

Read more
13 Mar 2020 16:04

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Mar 2020 14:07

Faron Pharmaceuticals Gets Green Light For New Traumakine Trial

Faron Pharmaceuticals Gets Green Light For New Traumakine Trial

Read more
9 Mar 2020 10:26

Faron gets FDA tick from proposed design of next 'Traumakine' study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design for the next 'Traumakine' study in acute respiratory distress syndrome (ARDS) patients, following its protocol submission in February.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.